Cardiovascular

With PCSK9s, payers say, 'Let the market decide'

With PCSK9s, payers say, 'Let the market decide'

By

It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.

New cardiovascular drugs raise concerns about pricing, efficacy

New cardiovascular drugs raise concerns about pricing, efficacy

By

With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.

Five things for pharma marketers to know: Tuesday, December 15, 2015

Five things for pharma marketers to know: Tuesday, December 15, 2015

By

Valeant agrees to cut prices in deal with Walgreens; FDA committee votes against Merck's Vytorin claims; Pacira settles off-label marketing case with the FDA

Five things for pharma marketers to know: Friday, December 11, 2015

Five things for pharma marketers to know: Friday, December 11, 2015

By

UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto

Five things for pharma marketers to know: Wednesday, December 2, 2015

Five things for pharma marketers to know: Wednesday, December 2, 2015

By

Negative news coverage of statins may lead people to stop taking their medication; second patient dies in Zafgen obesity drug trial; Gilead defends pricing

Five things for pharma marketers to know: Tuesday, November 10, 2015

Five things for pharma marketers to know: Tuesday, November 10, 2015

By

Aggressive treatment of blood pressure reduces deaths; AstraZeneca's experimental lupus drug cut disease activity in trial; Sophiris Bio reports results for enlarged prostate drug

Five things for pharma marketers to know: Monday, November 9, 2015

Five things for pharma marketers to know: Monday, November 9, 2015

By

More patients may be eligible for new PCSK9 inhibitors; Collegium's painkiller may receive FDA approval; MannKind's Afrezza reports slow sales

Novartis: Cardiologists slow to advocate on behalf of new drugs

Novartis: Cardiologists slow to advocate on behalf of new drugs

By

The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.

Five things for pharma marketers to know: Friday, October 23, 2015

Five things for pharma marketers to know: Friday, October 23, 2015

By

Amgen reportedly asks Repatha patients seeking financial assistance for personal health information; Valeant faces more scrutiny of business model; the FDA approves new J&J cancer drug

Five things for pharma marketers to know: Tuesday, October 13, 2015

Five things for pharma marketers to know: Tuesday, October 13, 2015

By

Lilly stops trial for experimental heart drug; Turing misses deadline to respond to lawmakers about price increase of Daraprim; the FDA expands indication for Opdivo

Express Scripts to cover Repatha and Praluent

Express Scripts to cover Repatha and Praluent

By

The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.

Five things for pharma marketers to know: Friday, September 18, 2015

Five things for pharma marketers to know: Friday, September 18, 2015

By

Oncologist says cancer drug prices defy markets; Jardiance slashes cardiovascular risk by one-third; Allergan wins approval for antipsychotic

Five things for pharma marketers to know: Friday, September 4, 2015

Five things for pharma marketers to know: Friday, September 4, 2015

By

Longer-term use of AstraZeneca's Brilinta approved; Google streamlines health-related searches; Zarxio's price is higher than expected

Five things for pharma marketers to know: Tuesday, September 1, 2015

Five things for pharma marketers to know: Tuesday, September 1, 2015

By

Amgen gives hefty discount to Repatha in Europe; Valeant partners with AstraZeneca on controversial psoriasis drug; Pfizer now offers single packages of Viagra

Five things for pharma marketers to know: Friday, August 28

Five things for pharma marketers to know: Friday, August 28

By

Amgen's Repatha receives FDA nod; Mylan shareholders vote in favor of Perrigo deal; doctors push for below-average price of experimental cancer drug

Five things for pharma marketers to know: Thursday, August 27

Five things for pharma marketers to know: Thursday, August 27

By

The FDA releases biosimilar-naming draft guidance; PD1 drugs linked to a rare type of diabetes; Amgen's PCSK9 inhibitor faces approval decision

Five things for pharma marketers to know: Monday, August 24

Five things for pharma marketers to know: Monday, August 24

By

AstraZeneca inks cancer development deal; beta-blockers may increase survival in ovarian-cancer patients; OPDP finds corrective ads are ineffective

New data sets up Jardiance  to displace DPP-4 inhibitors

New data sets up Jardiance to displace DPP-4 inhibitors

By

Eli Lilly's and BI's diabetes medication Jardiance becomes the first blood glucose-lowering drug to demonstrate it can reduce the risk of heart attack and stroke.

PCSK9 inhibitors necessitate an update to heart guidelines, CVS Health says

The pharmacy benefit manager said that the introduction of new treatments and clinical evidence on statins demands a rethink to ACC/AHA guidelines

Five things for pharma marketers to know: Monday, August 10

Five things for pharma marketers to know: Monday, August 10

By

CVS will not negotiate PCSK9 inhibitor pricing until Amgen's Repatha receives approval; more companies are looking inward for marketing help in lieu of agencies; AstraZeneca inks oncology collaboration

Five things for pharma marketers to know: Wednesday, August 5

Five things for pharma marketers to know: Wednesday, August 5

By

The FDA updates Gilenya's label over definite case of PML; generic drug companies are consolidating for negotiating power; the FDA revises guidance on DTC risk information

Pfizer ends bid for OTC Lipitor

Pfizer ends bid for OTC Lipitor

By

The drugmaker told investors that the actual-use trial failed to meet the primary objectives.

Five things for pharma marketers to know: Tuesday, July 28

Five things for pharma marketers to know: Tuesday, July 28

By

Sanofi plans immuno-oncology collaboration with Regeneron; Merck considers hard-to-treat patient populations for its experimental hepatitis-C therapy; drugmakers did not report 10% of adverse events to the FDA within required timeframe

FDA approves first PCSK9 inhibitor

FDA approves first PCSK9 inhibitor

By

The agency approved Sanofi's and Regeneron's Praluent, one of the most hyped new drugs of 2015.

Five things for pharma marketers to know: Friday, July 24

Five things for pharma marketers to know: Friday, July 24

By

UnitedHealth looks for refunds when drugs don't work; the European Medicines Agency recommends Sanofi's and Regeneron's PCSK9 inhibitor, Praluent, for approval; Biogen's multiple-sclerosis drug, Tecfidera, reports lower-than-expected sales growth

Five things for pharma marketers to know: Wednesday, July 15

Five things for pharma marketers to know: Wednesday, July 15

By

Celgene announces $7.2-billion bid for Receptos; Cytokinetics is using Ice Bucket Challenge donations to test experimental drug; GlaxoSmithKline conducts media review for its consumer health brands

Novartis bets on demand for new heart-failure drug Entresto

Novartis bets on demand for new heart-failure drug Entresto

By

The FDA approval this week of a new heart-failure drug is expected to spur interest among cardiologists seeking new ways to keep patients with heart failure out of the hospital.

Five things for pharma marketers to know: Wednesday, July 8

Five things for pharma marketers to know: Wednesday, July 8

By

CDC report finds prescription painkiller abuse contributed to an increase in heroin use; Novartis heart-failure drug gets FDA approval; Isis Pharmaceuticals obtains orphan-drug designation for volanesorsen

Five things for pharma marketers to know: Tuesday, June 30

Five things for pharma marketers to know: Tuesday, June 30

By

Vertex's cystic-fibrosis drug approval likely to come this week; Roche's multiple-sclerosis treatment hits primary and secondary endpoints; Regeneron/Sanofi debut film about high cholesterol

Five things for pharma marketers to know: Tuesday, June 23

Five things for pharma marketers to know: Tuesday, June 23

By

Adults dominate the ADHD prescription category; the FDA approved The Medicine Company's anticlotting drug 10 years after issuing a CRL; a survey shows personalized content can build consumer goodwill

Email Newsletters